Carlos Neideck

Carlos Neideck is a distinguished Principal Scientist at Boehringer Ingelheim, having joined the company in December 2022. Previously, Carlos contributed to Bayer Pharmaceuticals from September 2017 to December 2022, where roles included Research Scientist and Postdoctoral Researcher focusing on preclinical research in lung diseases. Carlos earned a PhD from Ludwig-Maximilians-Universität München, with a thesis investigating the chemokine/chemokine receptor system's role in atherosclerosis. Additional academic experience includes a Master’s thesis on IL-35 at Bernhard Nocht Institute for Tropical Medicine and various research assistant positions, with a strong emphasis on hematopoietic stem cell research and molecular biology. Education includes a Bachelor of Science in Biochemistry from Bielefeld University and a Master of Science in Molecular Life Science from the University of Hamburg.